Induction of CDK6 by tripartite motif-containing 59 (TRIM59) contributes to the epithelial-to-mesenchymal transition (EMT) process, while CDK4/6 mutations are associated with a poor prognosis in KRAS-mutant non-small-cell lung carcinoma (NSCLC), highlighting the role of CDK4/6 mutations as oncogenic factors that promote tumor growth and metastasis (17, 18). This evidence concerns the gene KRAS and neoplasm.